Vanguard Capital Management
MNPR icon

Vanguard Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Vanguard Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Sell
209,711
-8,752
-4% -$542K ﹤0.01% 2464
2026
Q1 		$12M Buy
+218,463
New +$13.2M ﹤0.01% 2631

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management's MNPR Position: Q2 2026 in Review

Vanguard Capital Management reduced its Monopar Therapeutics (MNPR) stake by 4% in Q2 2026, selling an estimated $542K and leaving 209,711 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2464.

Vanguard Capital Management first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Vanguard Capital Management held 209,711 shares of Monopar Therapeutics worth $19.4M as of Q2 2026.
  • Vanguard Capital Management sold 8,752 Monopar Therapeutics shares in Q2 2026, an estimated $542K.
  • Monopar Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2464 holding.
  • Vanguard Capital Management first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.